NeuBase Therapeutics, Inc.
NBSEDelisted May 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
13F holders, Q4 2023
Institutional positions in NeuBase Therapeutics, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +2 vs. Q3 2023
- Shares held
- 460.2K
- +128.9K (+38.9%) vs. Q3 2023
- Total value
- $340.2K
- +$52.6K (+18.3%) vs. Q3 2023
- New holders
- 3
- 2 more added
- Sold out
- 1
- 4 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NBSE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 2 | $4.95K |
| Q1 2024 | 18 | $177.1K |
| Q4 2023 | 21 | $340.2K |
| Q3 2023 | 20 | $301.2K |
| Q2 2023 | 26 | $1.08M |
| Q1 2023 | 36 | $1.72M |
| Q4 2022 | 35 | $1.94M |
| Q3 2022 | 44 | $4.74M |
| Q2 2022 | 43 | $13.4M |
| Q1 2022 | 45 | $23.3M |
| Q4 2021 | 46 | $31.6M |
| Q3 2021 | 48 | $36.6M |
| Q2 2021 | 59 | $51.5M |
| Q1 2021 | 57 | $59.4M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding NeuBase Therapeutics, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 300 | $0 | 0.00% | −362−54.7% | Reduced |
| Morgan Stanley | 9 | $6 | 0.00% | 00.0% | Unchanged |
| Global Wealth Management Investment Advisory, Inc. | 12 | $9 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 12 | $9 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 22 | $16 | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 21 | $16 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 79 | $58 | 0.00% | +14+21.5% | Added |
| BlackRock Inc. | 84 | $62 | 0.00% | −356−80.9% | Reduced |
| First Manhattan Co | 353 | $261 | 0.00% | −353−50.0% | Reduced |
| Bank of America Corp | 804 | $595 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,448 | $1.81K | 0.00% | +16+0.7% | Added |
| Geode Capital Management, LLC | 15,482 | $11.5K | 0.00% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 15,550 | $11.5K | 0.00% | 00.0% | Unchanged |
| Kestra Advisory Services, LLC | 16,476 | $12.2K | 0.00% | −1,500−8.3% | Reduced |
| Vanguard Group Inc | 18,981 | $14.0K | 0.00% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 21,083 | $15.6K | 0.00% | +21,083 | New |
| Carnegie Mellon University | 46,970 | $34.8K | 0.04% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 56,967 | $42.0K | 0.00% | +56,967 | New |
| Point72 Asset Management, L.P. | 62,500 | $46.3K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 65,724 | $48.6K | 0.00% | +65,724 | New |
| Greenlight Capital Inc | 136,350 | $100.9K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,354−100.0% | Sold out |
| Jacob Asset Management of New York LLC | – | – | – | – | Not filed |